PMID- 32418718 OWN - NLM STAT- MEDLINE DCOM- 20200901 LR - 20200901 IS - 1879-1913 (Electronic) IS - 0002-9149 (Linking) VI - 127 DP - 2020 Jul 15 TI - Measurement of Functional Capacity to Discriminate Clinical from Subclinical Heart Failure in Patients >/=65 Years of Age. PG - 84-91 LID - S0002-9149(20)30340-4 [pii] LID - 10.1016/j.amjcard.2020.03.051 [doi] AB - In order to show that reduced functional capacity in subclinical heart failure portends a higher risk of clinically overt (stage C) heart failure, we obtained the Duke activity status index (DASI) and 6-minute walk distance (6MWD) in 814 patients (age 70 [interquartile range 67 to 74] years, 51% female) with nonischemic subclinical heart failure. Reduced functional capacity was defined as: (1) DASI-derived metabolic equivalents <7, (2) 6MWD <2 standard deviations below the age-based normative mean (excluding those with mobility impairment) and (3) reduced 6MWD with reclassification where DASI was discordant. Based on reduced functional capacity and left ventricular dysfunction (LVD), subjects were classified into; (1) Stage A heart failure (436 with neither LVD nor reduced functional capacity), (2) Stage A with reduced functional capacity (n = 80), (3) Stage B heart failure (182 with LVD but preserved functional capacity) and (4) early stage C heart failure (52 with LVD and reduced functional capacity). Outcome was assessed by Kaplan-Meier survival estimates and Cox proportional hazard ratios. After a median follow-up of 13 months [interquartile range 11 to 19]), 76 (9%) developed heart failure - 6% of Stage A, 10% of Stage A-reduced functional capacity, 9% of Stage B and 37% of early Stage C (p < 0.001). After adjustment (for heart failure risk score, atrial fibrillation, pulmonary disease and therapy), the hazard ratio for development of overt heart failure in early Stage C was 5.92 (95% confidence intervals 2.92 to 11.54, p < 0.001) compared with Stage A and 3.08 (95% confidence intervals 1.47 to 6.47, p = 0.003) compared with Stage B. CI - Copyright (c) 2020 Elsevier Inc. All rights reserved. FAU - Potter, Elizabeth AU - Potter E AD - Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia; School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia. FAU - Yang, Hong AU - Yang H AD - Menzies Institute for Medical Research, Hobart, Tasmania, Australia. FAU - Wright, Leah AU - Wright L AD - Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia. FAU - Wang, Bing AU - Wang B AD - Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia; School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia. FAU - Marwick, Thomas H AU - Marwick TH AD - Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia; School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia. Electronic address: tom.marwick@baker.edu.au. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20200411 PL - United States TA - Am J Cardiol JT - The American journal of cardiology JID - 0207277 SB - IM MH - Aged MH - Exercise Test MH - Exercise Tolerance/*physiology MH - Female MH - Heart Failure/*diagnosis/physiopathology MH - Humans MH - Male MH - Prognosis MH - Risk Factors MH - Severity of Illness Index MH - Stroke Volume/*physiology MH - Ventricular Function, Left/*physiology EDAT- 2020/05/19 06:00 MHDA- 2020/09/02 06:00 CRDT- 2020/05/19 06:00 PHST- 2020/03/11 00:00 [received] PHST- 2020/03/30 00:00 [revised] PHST- 2020/03/30 00:00 [accepted] PHST- 2020/05/19 06:00 [pubmed] PHST- 2020/09/02 06:00 [medline] PHST- 2020/05/19 06:00 [entrez] AID - S0002-9149(20)30340-4 [pii] AID - 10.1016/j.amjcard.2020.03.051 [doi] PST - ppublish SO - Am J Cardiol. 2020 Jul 15;127:84-91. doi: 10.1016/j.amjcard.2020.03.051. Epub 2020 Apr 11.